Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Seika Forms JV with US Startup to Develop, Commercialize cGVHD Treatment
January 8, 2020
- Kyorin Grabs Japan Rights to aTyr’s Immunomodulator
January 7, 2020
- Taiho, Astex in KRAS Licensing Deal with US Merck
January 7, 2020
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- Eisai’s Fycompa Now Available in China
January 7, 2020
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- Sumitomo Dainippon Closes US$3 Billion Roivant Deal
January 7, 2020
- Urovant, Now under Sumitomo Dainippon, Seeks US Approval for Vibegron
January 7, 2020
- Eisai Discontinues Development of Epilepsy Drug after Death in PI; “Will Never Be Administered to Humans in the Future”
January 6, 2020
- Astellas Snaps Up US Biotech Xyphos for I/O Technology Platform
January 6, 2020
- Maruho Becomes Solasia’s 2nd Largest Shareholder
January 6, 2020
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- I/O Biotech BrightPath, Osaka Univ. Link Up for R&D of Immunostimulants
December 27, 2019
- Xofluza Most Detailed Drug for GPs in November: Impact Track
December 26, 2019
- IBL Inks Tick-Borne Disease Deal with South Korea Firm
December 26, 2019
- Nippon BI Chair Thorsten Poehl to Double as President after Merger; Yoshiaki Aono to Head Pharma Biz
December 26, 2019
- Fujifilm PII Alzheimer’s Study Gets Underway in Europe
December 26, 2019
- Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
- Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…